KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Research & Development: 2011-2024

Historic Research & Development for Neogenomics (NEO) over the last 14 years, with Dec 2024 value amounting to $31.2 million.

  • Neogenomics' Research & Development rose 13.14% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 18.31%. This contributed to the annual value of $31.2 million for FY2024, which is 14.10% up from last year.
  • According to the latest figures from FY2024, Neogenomics' Research & Development is $31.2 million, which was up 14.10% from $27.3 million recorded in FY2023.
  • Neogenomics' Research & Development's 5-year high stood at $31.2 million during FY2024, with a 5-year trough of $8.2 million in FY2020.
  • Over the past 3 years, Neogenomics' median Research & Development value was $30.3 million (recorded in 2022), while the average stood at $29.6 million.
  • In the last 5 years, Neogenomics' Research & Development spiked by 165.80% in 2021 and then dropped by 9.95% in 2023.
  • Yearly analysis of 5 years shows Neogenomics' Research & Development stood at $8.2 million in 2020, then skyrocketed by 165.80% to $21.9 million in 2021, then surged by 38.65% to $30.3 million in 2022, then decreased by 9.95% to $27.3 million in 2023, then increased by 14.10% to $31.2 million in 2024.